Navigation Links
Femina Pharma Announces ALJ's Denial of Merck's Motion for Summary Determination on Domestic Industry in ITC Patent Dispute Concerning NuvaRing®
Date:11/28/2011

MIAMI, Nov. 28, 2011 /PRNewswire/ -- Femina Pharma Incorporated announces the issuance of Order 24 in Investigation No. 337-TA-768 (In the matter of Certain Vaginal Ring Birth Control Devices) by the Administrative Law Judge at the United States International Trade Commission ("ITC") denying the Merck Respondents' Motion for Summary Determination on the basis of lack of Domestic Industry.  The issuance of Order 24 follows the prior issuance on July 15, 2011 of Order 14 denying Merck's Motion for Summary Determination of Invalidity of U.S. Patent No. 6,086,909.  

On February 11, 2011, Femina Pharma Incorporated filed a complaint with the ITC for infringement of the '909 patent through importation of certain vaginal ring birth control devices, including NuvaRing® against Merck & Co., Inc., Schering Plough Corporation, Organon USA, Inc., N.V. Organon, Wal-Mart Stores, Inc., CVS Pharmacy, Inc., Walgreen Co. and several Canadian On-Line Pharmacies.  The Canadian On-Line Pharmacies have been held in default.  NuvaRing® was acquired by Merck through its 2009 acquisition of Schering Plough.

Separately, Femina Pharma Incorporated announces the November 15, 2011 filing of a patent infringement lawsuit in federal district court in the Eastern District of Virginia against Merck & Co., Inc., Schering Plough Corporation, Organon USA, Inc., Wal-Mart Stores, Inc., CVS Pharmacy, Inc. and Walgreen Co. alleging infringement of the '909 patent by the NuvaRing® (C.A. no. 1:11cv1248) (the "District Action").  The District Action seeks monetary damages and injunctive relief.

Joseph Matus Fuisz, CEO of Femina Pharma, stated: "We are pleased with the Order denying the Merck Respondents' Motion for Summary Determination on the basis of lack of Domestic Industry. Femina continues to exploit the claimed technology and has every right to seek redress at the ITC to protect US industry from infringing foreign imports.  Femina Pharma initiated Investigation No. 337-TA-768 to stop the unlawful importation of infringing product sold as NuvaRing®.  We look forward to the ITC hearing scheduled for January 2012.  Separately, we have initiated the District Action to seek monetary damages for current and past infringement."

Merck & Co., Inc., Schering Plough Corporation, Organon U.S.A., Inc., N.V. Organon, CVS Pharmacy, Inc., Wal-Mart Stores, Inc. and Walgreen Co.'s are represented in the ITC action by Covington & Burling, LLP. Femina Pharma Incorporated is represented in both the ITC and the District Action by The Fuisz-Kundu Group LLP (www.fuiszkundu.com).

About Femina Pharma Incorporated:

Femina Pharma Incorporated is a vaginal drug delivery company formed through the acquisition of the vaginal drug delivery assets of UMD Inc. Femina Pharma is managed by Joseph Fuisz and Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz). The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma (www.fuisz.com).

 


'/>"/>
SOURCE Femina Pharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
2. ShangPharma to Attend Two Upcoming Investor Conferences
3. Pharmaceutical Packaging Industry - 2011 Yearbook
4. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
5. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
6. Endo Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Leveraged Finance Conference
7. Isis Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
8. AcelRx Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
9. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
10. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
11. Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps ... fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization GenCure, ... at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood donations ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB since ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... Bill ... management industry in the coastal communities. After Tina Howe joined the team, the Bill ... happy employees, honest services at affordable rates, and giving back to the San Diego ...
Breaking Medicine News(10 mins):